Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
19
9
2020
medline:
29
7
2021
entrez:
18
9
2020
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) is a chronic and disabling disorder. Severity of IBD is prominent among refractory with patients with concomitant immune-mediated disorders. Among those patients, dual biological therapy (DBT) has been suggested as an alternative approach to spare steroids and avoid surgery. However, pieces of evidence on clinical outcomes among patients receiving DBT are still limited. We present two cases of IBD patients, with dermatological comorbidity, treated with a combination of vedolizumab and ustekinumab, identifying possible landmarks to address therapeutic choice. No patient experienced adverse events in the follow-up period and both obtained complete clinical remission. DBT may be an effective approach to consider in selected patients with refractory IBD with concomitant severe immune-mediated diseases taking into account medical history of the patient, presence, and type of concomitant extraintestinal manifestations, safety profile of selected DBT, licensed therapeutic indications, and costs.
Identifiants
pubmed: 32947419
doi: 10.1097/MEG.0000000000001919
pii: 00042737-202012000-00014
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
vedolizumab
9RV78Q2002
Ustekinumab
FU77B4U5Z0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1579-1582Références
Ramos GP, Papadakis KAMechanisms of disease: inflammatory bowel diseasesMayo Clin Proc201994155165
Tindemans I, Joosse ME, Samsom JNDissecting the heterogeneity in T-cell mediated inflammation in IBDCells2020piiE110
Im JP, Ye BD, Kim YS, Kim JSChanging treatment paradigms for the management of inflammatory bowel diseaseKorean J Intern Med2018332835
Patel H, Lissoos T, Rubin DTIndicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United StatesPLoS One201712e0175099
Molander P, Kemppainen H, Ilus T, Sipponen TLong-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseasesScand J Gastroenterol2020553440
Juillerat P, Manz M, Sauter B, Zeitz J, Vavricka SRSwiss IBDnetTherapies in inflammatory bowel disease patients with extraintestinal manifestationsDigestion202017115
Holmer A, Singh SOverall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseasesExpert Rev Clin Immunol201915969979
Hirten RP, Iacucci M, Shah S, Ghosh S, Colombel JFCombining biologics in inflammatory bowel disease and other immune mediated inflammatory disordersClin Gastroenterol Hepatol20181613741384
Ribaldone DG, Pellicano R, Vernero M, Caviglia GP, Saracco GM, Morino M, Astegiano MDual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysisScand J Gastroenterol201954407413
Kwapisz L, Raffals LE, Bruining DH, Pardi DS, Tremaine WJ, Kane SV, et al.Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care centerClin Gastroenterol Hepatol2020piiS1542-3565(20)30186-5
Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, et al.Unmet medical needs in the management of ulcerative colitis: results of an Italian Delphi consensusGastroenterol Res Pract201920193108025
Ben-Horin S, Chowers YReview article: loss of response to anti-TNF treatments in Crohn’s diseaseAliment Pharmacol Ther201133987995
Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, et al.Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysisClin Gastroenterol Hepatol201917838846.e2
Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, et al.Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapyAliment Pharmacol Ther2018486577
Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al.Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s diseaseGut201968814828
Digby-Bell JL, Atreya R, Monteleone G, Powell NInterrogating host immunity to predict treatment response in inflammatory bowel diseaseNat Rev Gastroenterol Hepatol202017920
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al.SONIC Study GroupInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med201036213831395
Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al.Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2014146392400.e3
Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al.Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximabInflamm Bowel Dis200713211
Le Berre C, Loeuille D, Peyrin-Biroulet LCombination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathyClin Gastroenterol Hepatol201917794796
Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HHTofacitinib for the treatment of pyoderma gangrenosumClin Gastroenterol Hepatol201917991993
Peyrin-Biroulet L, Demarest S, Nirula ABispecific antibodies: the next generation of targeted inflammatory bowel disease therapiesAutoimmun Rev201918123128
Patel RI, Beckett RDEvaluation of resources for analyzing drug interactionsJ Med Libr Assoc2016104290295
Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow GSerological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapyScand J Gastroenterol201752414419
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al.Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-targetAm J Gastroenterol201511013241338
Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, Pittet VEHSwiss IBD Cohort Study GroupThe evolution of health care utilisation and costs for inflammatory bowel disease over ten yearsJ Crohns Colitis201913744754
Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla RPrecision medicine in inflammatory bowel disease: concept, progress and challengesF1000Res2020piiF1000FacultyRev-54